Haematology

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

News

Filmmaker helps AbbVie spread the word about leukaemia

AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

FDA starts priority review of BeOne's Venclexta rival

NICE backs NHS use of Autolus' leukaemia CAR-T

Agios shares slump on sickle cell disease data

Filmmaker helps AbbVie spread the word about leukaemia

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

GSK's Blenrep's back in US, but with a narrower label

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Haematology

Editor's Picks